Bio-Path Reports Meaningful Progress Across Key Clinical Trials In Multiple Cancer Indications

Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, said, "With the increased clinical data that we have generated, we are now able to develop the biomarkers needed to incorporate into our oncology studies. In addition, we have completed preparations for preclinical work to support advancing prexigebersen as a potential treatment for obesity. In tandem, we are designing development plans for first-in-human clinical studies in this expansive global market for weight loss."